FCGR1A and acute myeloid leukemia: In terms of myeloid neoplasms, CRISPR screening has uncovered the genes that sensitize AML cells to double-negative T-cell therapy, highlighting CD64 as a predictive marker for response to this treatment in AML patients [274].